Double attack on tough cancers: early trial tests combo for patients out of options
NCT ID NCT04673448
Summary
This early-stage trial is testing a combination of two drugs, niraparib and dostarlimab, for people with advanced breast, ovarian, pancreatic, or related cancers that have a specific genetic change (BRCA mutation) and have stopped responding to standard treatments. The goal is to see if the two drugs working together—one targeting cancer cell repair and the other boosting the immune system—can better control the cancer. The study will enroll a small group of 18 participants to first assess safety and see if the treatment shows promise.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.